The Effect of Enamel Matrix Derivative (Emdogain®) on Bone Formation: A Systematic Review

Florian Rathe, Dr. med. dent.,¹ Rüdiger Junker, Dr. med. dent., M.Sc.,¹ Betsy M. Chesnutt, M.Sc.,^{1,2} and John A. Jansen, D.D.S., Ph.D.¹

This systematic review focused on the question, if and to what extent enamel matrix derivative (Emdogain® [EMD]) promotes the regeneration of bone. The influence of combinations with other biomaterials was additionally evaluated. Twenty histomorphometric studies were included in this systematic review. Main results of the reviewed articles were (i) guide tissue regeneration (GTR) of infrabony defects seems to result in a higher degree of bone regeneration compared to treatment with EMD; (ii) combined therapy (GTR + EMD) of infrabony defects might not lead to better results than GTR therapy alone; (iii) there seems to be no additional benefit of combined therapy (GTR + EMD) in furcation defects over GTR therapy alone; (iv) EMD seems to lead to more bone regeneration of infrabony defects compared to open flap debridement; (v) however, EMD application might result in more bone formation when applied in supporting defects compared to nonsupporting defects; and (vi) EMD does not seem to promote external jaw/parietal bone formation in the titanium capsule model. The results of one study that suggest that EMD increases the initial growth of trabecular bone around endosseous implants by new bone induction need to be confirmed by additional research.

Introduction

PERIODONTAL REGENERATION is defined as the reproduction or reconstruction of lost or injured tissue so that the form and function of the lost structures are restored. In order to fulfill the criteria set by the American Academy of Periodontology,¹ periodontal regeneration has to include regeneration of cementum, functionally aligned periodontal ligament, alveolar bone, and gingiva.

Histological findings and clinical results are suggestive that regeneration of root cementum, periodontal ligament, and alveolar bone can in fact occur in human infrabony defects resulting from chronic periodontitis.^{2,3}

Several studies have demonstrated that the use of enamel matrix derivative (Emdogain® [EMD]), a commercially available purified acidic extract by porcine enamel matrix containing the hydrophobic protein assembly of amelogenins, in periodontal regenerative surgery appears to favor the formation of new attachment characterized by the presence of new acellular and/or cellular cementum with inserting collagen fibers and new alveolar bone.⁴⁻⁹ However, alveolar bone formation following the use of EMD has been reported to be minimal in spite of the presence of significant amounts of new cementum.^{5,10,11} Up to now, the effect of EMD on bone formation is not well understood.

In vivo, EMD stimulates bone regeneration of rat femurs,¹² and it accelerates new bone formation in rat skull defects¹³; further, it has been shown that it contains both transforming growth factor- and bone morphogenetic protein-like growth factors that contribute to the induction of mineralization during periodontal regeneration.¹⁴ However, EMD failed to show any significant benefit in promoting new bone formation around titanium implants in rabbits.¹⁵ This systematic review focuses on the question, if and to what extent EMD promotes the regeneration of bone. The influence of combinations with other biomaterials was additionally evaluated.

Materials and Methods

Search strategy

A systematic literature search in electronic databases (PubMed and Cochrane Library) was conducted, using the following search term combination: "(emdogain OR EMD OR enamel matrix derivative OR enamel matrix proteins) AND (bone formation OR bone regeneration OR new bone formation OR osteogenesis)."

Further, a manual search in the references of the selected papers was performed, focusing on articles related to the effect of EMD on bone regeneration.

¹Department of Periodontology and Biomaterials, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

²Department of Biomedical Engineering, University of Memphis, Memphis, Tennessee.

TABLE 1. STUDIES EXCLUDED FROM SYSTEMATIC REVIEW

Study	Subjects	Sites investigated	Reason for exclusion
Bosshardt <i>et al.</i> ⁹	Human	Periodontal infrabony defects	No histomorphometry performed
Gurinsky <i>et al.</i> ⁵⁶	Human	Periodontal infrabony defects	No histomorphometry performed
Mellonig ⁴	Human	Periodontal infrabony defects	No histomorphometry performed
Sculean <i>et al.</i> ⁵¹	Human	Periodontal infrabony defects	No histomorphometry performed
Yukna and Mellonig ⁸	Human	Periodontal infrabony defects	No histomorphometry performed
Boyan <i>et al.</i> ⁵⁹	Animal	Mouse calf muscle	Ectopic bone formation investigated
Donos <i>et al.</i> ⁵⁸	Animal	Calvarial defects	No histomorphometry performed
Donos <i>et al.</i> ⁵⁷	Animal	Rat pectoralis profundi muscle	Ectopic bone formation investigated
Kanazashi <i>et al.</i> ⁵⁵	Animal	Periodontal buccal dehiscence defects	No bone formation investigated
Kawana <i>et al.</i> ¹²	Animal	Rat femur	No histomorphometry performed
Koike <i>et al.</i> ⁵⁴	Animal	Rat rectus abdominis muscle	Ectopic bone formation investigated
Nemcovsky <i>et al.</i> ⁵³	Animal	Periodontal intra-suprabony defects	Mostly suprabony defects
Sculean <i>et al.</i> ⁵²	Animal	Fenestration-type defects	Defects healed spontaneously in all groups
Yoneda <i>et al.</i> ¹³	Animal	Rat skull defect	No histomorphometry performed

Inclusion criteria

A literature search was performed to identify meta-analysis, systematic reviews as well as randomized-controlled clinical trials (RCTs), case reports, or case series.

Publications were considered for systematic review, if they were published until June 2007 in English language and listed in the electronic databases, PubMed or Cochrane Library, or were listed as reference in selected articles.

All articles had to provide histomorphometric data concerning the question if and to what extent EMD affects bone regeneration.

Selection of studies

Titles and abstracts of the publications identified by electronic databases were screened initially by two reviewers (F.R. and R.J.). Publications were included for full-text evaluation if the content of the abstracts met the inclusion criteria and matched to the focused question. Disagreement between the reviewers was resolved by evaluation of the full texts and discussion. Final authority for selection disagreements rested with R.J. Full-text assessment was performed by the reviewers without any disagreements. A manual search was performed among the references of the selected publications after full-text assessment.

Exclusion criteria

Publications were excluded if they did not meet the inclusion criteria (i.e., no histomorphometric analysis performed), or evaluated osteoinductive properties of EMD (i.e., ectopic bone formation), or did not provide relevant data for the focused question. Excluded studies and reasons for exclusion are listed in Table 1.

Results

Twenty studies were included for systematic review; studies were summarized in Tables 2 and 3. Of these 20 studies, 5 reported on human data. Three of these were case reports,^{10,16,17} and two were RCTs.^{5,11} The remaining 15 studies reported on data obtained from animal studies.

Results from human studies

The postoperative protocol was the same in three studies^{5,10,11} and consisted of 1 g amoxicillin per day for 1 week postsurgery; patients were not allowed to perform oral hygiene at the surgical sites for 4 weeks and were instructed to rinse twice per day with 0.2% chlorhexidine mouth rinse during that time. Subsequently, professional prophylaxis was performed once every second week during the entire

TABLE 2. STUDIES REPORTING ON HUMAN DATA

Study	Type of defect	Sample size (number of defects)	Treatment groups	Results (mm of new bone formation/% of defect fill with new bone)	Histology performed (time allowed for healing)
Heijl ¹⁶	Periodontal buccal dehiscence	<i>n</i> = 1	EMD	65%	4 months
Majzoub <i>et al.</i> ¹⁷	Periodontal infrabony	<i>n</i> = 1	EMD	3.63 mm	9 months
Sculean <i>et al.</i> ⁵	Periodontal infrabony	<i>n</i> = 14	G1: EMD G2: GTR	0.9 ± 1.0 mm 2.1 ± 1.0 mm	6 months
Sculean <i>et al.</i> ¹⁰	Periodontal infrabony	<i>n</i> = 2	EMD	0 and 1.7 mm	6 months
Windisch <i>et al.</i> ¹¹	Periodontal infrabony	<i>n</i> = 14	G1: EMD G2: GTR	0.78 ± 0.97 mm 1.93 ± 1.04 mm	6 months

TABLE 3. STUDIES REPORTING ON ANIMAL DATA

Study	Type of defect	Sample size (number of defects)	Treatment groups	Results (mm of new bone formation/% of defect fill with new bone)	Histology performed (time allowed for healing)
Casati <i>et al.</i> ²⁶	Implant buccal dehiscence	$n = 48$	G1: EMD	55.55 ± 11.81% NBA	3 months
			G2: EMD + GBR	62.15 ± 18.47% NBA	
			G3: GBR	53.89 ± 16.35% NBA	
			G4: negative control	36.95 ± 25.10% NBA	
Cochran <i>et al.</i> ¹⁸	Periodontal infrabony	$n = 40$	G1: EMD in 1-mm-wide defects	2.86 mm	5 months
			G2: OFD in 1-mm-wide defects	2.48 mm	
			G3: EMD in 2-mm-wide defects	3.14 mm	
			G4: OFD in 2-mm-wide defects	2.11 mm	
			G5: EMD in 4-mm-wide defects	1.22 mm	
			G6: OFD in 4-mm-wide defects	1.78 mm	
			G7: EMD in 6-mm-wide defects	2.01 mm	
			G8: OFD in 6-mm-wide defects	1.89 mm	
Donos <i>et al.</i> ²³	Class III furcation	$n = 12$	G1: EMD	71.95 ± 21.3%	5 months
			G2: EMD + GTR	73.3 ± 11.8%	
			G3: GTR	59.8 ± 32.5%	
			G4: CAF	43.9 ± 6.1%	
Donos <i>et al.</i> ²⁸	PTFE capsule	$n = 16$	G1: capsule + EMD	17.5%	120 days
			G2: capsule + DBBM	15.1%	
			G3: capsule + EMD + DBBM	12.0%	
			G4: capsule	39.7%	
Fernandes <i>et al.</i> ²⁴	Class III furcation	$n = 20$	G1: EMD + GTR	0.1 ± 0.3%	90 days
			G2: EMD + GTR + BG	2.0 ± 2.9%	
Hammarström <i>et al.</i> ²¹	Periodontal buccal dehiscence	$n = 94$	G3: GTR + BG	0.8 ± 1.7%	8 weeks
			G1: homog. enamel matrix	54%	
			G2: amelogenin	73%	
			G3: enamelin	0%	
Murai <i>et al.</i> ²⁹	Calvarial	$n = 28$	G4: EMD	67%	1 month
			G5: OFD	2%	
			G1: cap + β-TCP + EMD	42.2 ± 13.1%	
			G2: cap + β-TCP	36.8 ± 10.3%	
Onodera <i>et al.</i> ¹⁹	Periodontal infrabony	$n = 24$	G1: cap + β-TCP + EMD	43.3 ± 6.8%	3 months
			G2: cap + β-TCP	41.2 ± 10.6%	
			G1: GTR	55.2 ± 0.1%	
			G2: GTR + EMD	77.6 ± 0.2%	
Regazzini <i>et al.</i> ²⁵	Class II furcation	$n = 24$	G1: GTR	90.1 ± 0.12%	8 weeks
			G2: GTR + EMD	98.3 ± 0.04%	
			G1: EMD	67.36 ± 3.93%	
			G2: EMD + GTR	28.49 ± 10.32%	
			G3: OFD	31.65 ± 6.06%	

(Continued)

TABLE 3. (CONTINUED)

Study	Type of defect	Sample size (number of defects)	Treatment groups	Results (mm of new bone formation/% of defect fill with new bone)	Histology performed (time allowed for healing)
Sallum <i>et al.</i> ²²	Periodontal buccal dehiscence	<i>n</i> = 24	G1: EMD	2.01 ± 0.82 mm	4 months
			G2: GTR	0.91 ± 1.08 mm	
			G3: EMD + GTR	1.40 ± 1.08 mm	
			G4: OFD	1.14 ± 0.39 mm	
Sawae <i>et al.</i> ³⁰	Parietal	<i>n</i> = 10	G1: EMD	0.97 ± 0.04%	60 days
			G2: PGA	0.74 ± 0.17%	
Sculean <i>et al.</i> ⁶	Periodontal infrabony	<i>n</i> = 24	G1: EMD	1.4 ± 0.9 mm	5 months
			G2: GTR	2.0 ± 1.1 mm	
			G3: EMD + GTR	2.1 ± 1.1 mm	
			G4: CAF	0.7 ± 1.1 mm	
Shimizu <i>et al.</i> ²⁷	Bone-to-implant contact	<i>n</i> = 10	G1: EMD	12.82 ± 1.42% ^a	30 days
			G2: PGA	9.88 ± 2.31% ^a	
Shirakata <i>et al.</i> ²⁰	Periodontal infrabony	<i>n</i> = 16	G1: α -TCP	3.58 ± 0.79 mm	10 weeks
			G2: α -TCP + EMD	3.07 ± 0.62 mm	
			G3: EMD	2.33 ± 0.92 mm	
			G4: OFD	1.95 ± 0.8 mm	
Stenport and Johansson ¹⁵	Bone-to-implant contact	<i>n</i> = 36	G1: EMD	10 ± 8% BMC	6 weeks
			G2: PGA	12 ± 3% BMC	
			G1: EMD	53 ± 16% NBA	
			G2: PGA	58 ± 11% NBA	
			G1: EMD	4.5 ± 2.0% BL	
			G2: PGA	6.0 ± 1.8% BL	

^a% of newly formed trabecular bone/medullary cavity after 30 days.

BG, bioactive glass; CAF, coronal advanced flap; BMC, bone-to-metal contact; BL, bone length.

study period. One study did not provide information about performed postoperative care,¹⁶ and one study reported the use of 200 mg doxycycline per day for 10 days postsurgery.¹⁷ The patient of this case report was instructed to rinse with 0.2% chlorhexidine three times daily for 6 weeks following surgery; the patient was recalled monthly for professional supragingival plaque control during the first 6 months postoperatively and every 3 months thereafter.

One buccal dehiscence defect in one case report¹⁶ was surgically created. All other defects resulted from chronic periodontitis, and patients received full mouth scaling and root planing under local anesthesia 3 months prior to surgical procedures.

In two case reports, 37% orthophosphoric acid was applied for 15 s for root conditioning prior to application of EMD,^{16,17} whereas 24% ethylenediaminetetraacetic acid (EDTA) was administered for 2 min in the other three studies.^{5,10,11}

Clinical healing was uneventful in all defects of all studies throughout the study periods, and no subjective adverse experiences were recorded.

New bone formation after treatment and the time point of histomorphometry are presented in Table 2.

In one case report,¹⁶ a buccal dehiscence defect was created surgically at tooth 31 of a 49-year-old nonsmoking male and extended from the mesial to the distal line angle (at the line angle, the flat tooth surface converts into the curvature)

and was almost reaching the apex (exact defect size is not mentioned).

Majzoub *et al.*¹⁷ reported on treatment with EMD of a mandible first molar of a 46-year-old woman presenting with a deep infrabony defect. The intraoperative morphology of the defect at the distal root demonstrated a deep infrabony circumferential defect involving all four surfaces of the root with an infrabony component of 8.5 mm; further, the tooth presented a trough and through furcation involvement. Two distinct healing patterns were evident 9 months after EMD treatment. At the distal surface of the distal root, new bone extended 3.63 mm coronal to the reference notch, which seemed to parallel cementum deposition throughout most of the defect, whereas an ankylosis was present at the furcal surface.

Two combined one- and two-walled advanced infrabony defects (maxillary left central incisor) had been treated with EMD in two patients aged 50 and 55 years in the third case report reviewed.⁵

Both RCTs^{5,11} evaluated periodontal regeneration of advanced infrabony defects following the treatment with EMD or guided tissue regeneration (GTR) using bioabsorbable membranes (Resolut[®]). Fourteen infrabony defects were treated in each study, which were equally distributed to each group in the study from Sculean *et al.*⁵ In the study of Windisch *et al.*,¹¹ eight defects were treated with GTR pro-

cedure and six with the use of EMD. Further, all patients were nonsmokers in the study of Sculean *et al.*,⁵ whereas one smoker was treated with GTR procedure and two smokers were treated with EMD in the investigation of Windisch *et al.*¹¹ No membrane exposure was noted in either study. Both studies found a significant difference in new bone formation favoring the GTR treatment (Table 2). In 5 out of 13 specimens, no new bone formation could be evaluated histologically after EMD treatment; further, bone regeneration was minimal (0.2–0.5 mm) in four further defects. In the remaining four defects of the EMD group, bone regeneration could be evaluated with a range of 1.8–2.2 mm. Infrabony defects treated with GTR showed at least minimal bone formation (0.1 and 0.2 mm) in 2 defects, whereas the 12 remaining defects showed bone regrowth within a range of 1–3 mm.

Results from animal studies

Infrabony and dehiscence defects. All studies mentioned here investigated standardized periodontal infrabony^{6,18–20} or dehiscence-type^{21,22} defects, either in monkeys^{6,18,21} or dogs.^{19,20,22} In four studies,^{6,18,19,22} ligature-induced inflammation was provoked after surgical defect creation to prevent spontaneous healing. In all studies, the postoperative protocol comprised the administration of antibiotics, whereas plaque control was only performed in four studies after regenerative therapy.^{6,19,20,22} In most studies, root conditioning was only performed when EMD was applied.^{6,18–20,22} Three studies^{19–21} used phosphoric acid (concentration varied between 35% and 37% for 15 s), and all other studies^{6,18,22} used EDTA-gel (concentration 24% for 2 min).

The sample size, type of defect, treatment modality, results, and time allowed for healing are presented in Table 3 for all studies reporting on animal data.

In the studies of Sculean *et al.*⁶ and Onodera *et al.*,¹⁹ infrabony defects of approximately 6- to 8-mm depth were created, but no information was given about the amount of bony walls. While reading the surgical procedure, one can assume that one- or two-wall defects were created. For the GTR procedure, either bioresorbable barrier membrane (Resolute[®]) or nonresorbable extended-polytetrafluorethylene (e-PTFE) membrane (Gore-Tex[®]) was used.

In the study of Sculean *et al.*,⁶ a great amount of sites experienced membrane exposure; two sites (one of the GTR group and one of the GTR + EMD group) had to be excluded from histological evaluation because of early membrane exposure during the second postoperative week. Another site from the GTR group had to be excluded due to failure during histological processing. There were four additional sites showing membrane exposure in the third postoperative week (two of the GTR group and two of the GTR + EMD group). Those four sites were not excluded from histological evaluation, so that only two out of the four evaluated sites in the GTR group and three out of five sites of the GTR + EMD group experienced no membrane exposure. Even so, the most new bone formation was detected after the use of a barrier membrane.

No postoperative membrane exposure is mentioned in the study by Onodera *et al.*¹⁹ In this study, no bone formation was evident 1 week after regenerative surgery in either group, but 2 (results not shown) and 4 weeks after surgery, significantly more bone formation ($p < 0.05$) could be de-

termined in the combined group (GTR + EMD, Onodera *et al.*¹⁹). However, 8 weeks postsurgery, no significant differences could be found between the two treatment groups.

The healing of standardized one-wall periodontal defects of 5×5×4 mm²⁰ and defects of standardized depth with varying width in the mesiodistal direction¹⁸ was investigated in two further studies. Shirakata *et al.*²⁰ found no significant differences between EMD (G3) and open flap debridement (OFD) (G4) groups or between the EMD + α -tricalcium phosphate (TCP) (G2) and α -TCP (G1) groups (Table 3). However, if G3 and G4 are compared with G1 and G2 (G4 vs. G1 or G2, $p < 0.0001$; G3 vs. G1, $p < 0.0001$; G3 vs. G2, $p = 0.0057$), significantly more bone formation was determined in the EMD + α -TCP (G2) and α -TCP (G1) groups. The study of Cochran *et al.*¹⁸ showed that EMD applied in narrow defects (1- and 2-mm-wide defects) resulted in 3.00-mm new bone compared to 2.29 mm of new bone for the control treatment, a 31% increase in bone height. In wider lesions (4- and 6-mm-wide defects), the amount of new bone was similar between EMD-treated sites and controls (1.67 and 1.84 mm).

Buccal dehiscence defects in both studies were approximately 6-mm deep,^{21,22} whereas the width of the defect (4 mm) was only mentioned in the article by Sallum *et al.*²² In the study by Hammarström *et al.*,²¹ which was performed to explore the effect of locally applied enamel matrix and different protein fractions of the matrix on periodontal regeneration, it was shown that it is possible to obtain regeneration of 54–73% of bone tissues by applying the whole enamel matrix, the acid extract (amelogenin), or EMD in the buccal dehiscence model. Sallum *et al.*²² utilized nonresorbable barrier membranes (Resolute) for the GTR procedure, and only one membrane of the EMD + GTR group experienced exposure in the first postoperative week. Regarding new bone formation, no statistically significant differences were observed among the groups (Table 3).

Furcation defects. Different regenerative procedures (Table 3) were evaluated in standardized furcation defects in monkeys²³ and dogs.^{24,25} Two studies investigated class III furcation involvement with a vertical dimension of 3–4 mm²³ and 5 mm.²⁴ Regazzini *et al.*²⁵ created class II furcation defects with a vertical dimension of 5 mm and a horizontal component of 2 mm, which equals a class II furcation in dogs. Plaque formation with subsequent inflammation of the defect was provoked in all studies after surgical defect creation. Following regenerative surgery antibiotics were administered in all investigations, as well as plaque control regimens. Root conditioning was performed only in combination with EMD treatment in two studies,^{23,24} whereas root surfaces of the control defects also received root conditioning in the trial of Regazzini *et al.*²⁵ EDTA-gel (24%) applied for 2 min was used in all studies for root conditioning. Resorbable membranes (Resolute²³ and Resolute XT^{®24}) were utilized in two studies, and nonresorbable e-PTFE barrier membranes (Gore-Tex) were used in one study.²⁵

Membranes were exposed 15 days after surgery in the study of Regazzini *et al.*,²⁵ but no information about the amount of exposed membranes was provided. No significant difference in terms of new bone formation was evident between the EMD + GTR group and the control treatment, but EMD treatment alone resulted in significant more bone

formation ($p < 0.05$) compared to groups EMD + GTR and OFD (for results see Table 3). In the experimental trial of Donos *et al.*,²³ exposure of the membrane occurred in two sites treated with GTR alone during the second postoperative week. In the third postoperative week, a defect treated with the combination of GTR and EMD presented exposure of the membrane. Additionally, one defect treated with EMD experienced recession of the flap to the level of the fornix of the furcation (for results see Table 3). No postoperative membrane exposure was mentioned in the study by Fernandes *et al.*²⁴ Statistical analysis of the treatment outcome did not show significant differences among the different groups for linear and area measurements; however, it must be pointed out that no negative control group (e.g., OFD) was evaluated (for results see Table 3).

Periimplant defects and bone-to-implant contact. Casati *et al.*²⁶ created buccal dehiscence defects (3.5×5.0 mm) in dogs before and 2 months after implant (3.75×8.5 mm; screw-shaped pure titanium) placement. The buccal dehiscence defects were treated with various regenerative procedures (Table 3; Resolute XT was used for guided bone regeneration [GBR]), and the postoperative protocol consisted of administration of antibiotics and daily plaque control until the animals were sacrificed. The percentage of bone-to-implant contact and new bone area (NBA) within the limits of the previously exposed threads of each implant were determined. After 3 months, no statistically significant differences were observed among the groups in terms of bone-to-implant contact (results not shown). However, the EMD + GBR group presented a greater ($p < 0.05$) area of new bone when compared to the control group. The groups treated by EMD or GBR alone showed no statistically significant differences in NBA when compared to controls or to the EMD + GBR group (Table 3). Thirty-six screw-shaped pure titanium implants (3.75×8.0 mm) were placed in rabbit femurs in the study by Stenport and Johansson.¹⁵ Immediately prior to implant insertion, either EMD or its vehicle gel (propylene glycol alginate [PGA]) alone was placed into the surgically created implant site. The percentage of bone-to-metal contact and bone area were measured in all threads as well as the entire bone length along the implant surface, but the differences were not statistically significant. Shimizu *et al.*²⁷ inserted cylinder-shaped mini titanium implants (1.6×3.5 mm) with filling of medullary cavities with either EMD or its carrier. Mean percentage of newly formed trabecular bone per medullary cavity was assessed. In morphometric analysis, newly formed trabecular bone area within medullary cavities was significantly ($p < 0.05$) greater in EMD-treated femurs than in PGA-treated femurs 30 days postimplantation.

Bone formation in experimental capsule and parietal model. Donos *et al.*²⁸ placed hemispherical PTFE capsules (internal diameter: 5 mm and wall thickness: 0.5 mm) with openings facing the lateral aspect of the mandible ramus of Wistar rats. The animals were randomly allocated to four treatment groups (Table 3). Percentage of newly formed bone of the maximal possible space created by the capsule was determined by planimetric measurements. The PTFE capsule had been slightly displaced during healing in three out of five specimens of group 1, in one out of three of group 2, in

three out of four of group 3, and in two out of five in group 4 (Table 3), which resulted in a less-favorable treatment outcome compared to those capsules that had not been displaced. Statistically significant differences could be evaluated between capsule-alone group and capsule + deproteinized bovine bone mineral (DBBM) ($p = 0.034$) and capsule + DBBM + EMD ($p = 0.021$) groups, favoring the capsule-alone group in terms of new bone formation. In other words, there was no significant difference between capsule-alone group and capsule + EMD, whereas adding DBBM led to less-favorable results. The PTFE capsule model has also been utilized in rabbit calvarium by Murai *et al.*²⁹ The capsules were filled either with β -TCP + EMD or with β -TCP alone (Table 3). After both 1 ($p = 0.075$) and 3 months of healing (Table 3; $p = 0.92$), no significant differences in the amount of newly formed bone were found between test and control capsules. Sawae *et al.*³⁰ perforated the parietal bones of Wistar rats with a sterile round bur (0.8-mm diameter). The injured bone areas were immediately filled with EMD (test) or its PGA-carrier (control) and allowed to heal for 4, 7, 14, 30, and 60 days. The results were expressed as the mean percentages of newly formed bone areas per perforated space. Morphometric analysis showed that at only 60 days post-surgery, new bone formation in the EMD-treated parietal bones was significantly ($p < 0.05$) greater than that seen in PGA-treated controls (Table 3).

Discussion

The aim of this systematic review was to evaluate the osteopromotive properties of EMD *in vivo*, since it has not been done before. Twenty studies were included for systematic review. Five reported on human data with three of these being case reports and two being RCTs. The remaining 15 studies reported on data obtained from animal studies.

Unfortunately, none of the histomorphometric studies reporting on human data compared the amount of bone regeneration in periodontal defects after the use of EMD with a control surgery (i.e., OFD and coronal advanced flap). If bone regrowth was evaluated after the use of EMD and compared with results obtained after utilizing the GTR therapy with resorbable membranes, GTR therapy resulted in a higher degree of bone regeneration than treatment with EMD (Table 2^{5,10,11}).

The amount of bone regrowth after the use of EMD in the two cases reported by Sculean *et al.*¹⁰ is in accordance with the minimal bone regrowth reported by Sculean *et al.*⁵ and Windisch *et al.*¹¹ Heijl¹⁶ published outstanding results with respect to bone regeneration. He achieved a bone regrowth of 65% of the presurgical bone height of a buccal dehiscence defect reaching almost the apex. The discrepancy between the results reported by Sculean *et al.*^{5,10} and Windisch *et al.*¹¹ and the case of Heijl¹⁶ can be explained, at least in part, by spontaneous healing, since the buccal dehiscence defect treated by Heijl¹⁶ was of an acute type (i.e., defect was surgically created and immediately treated without previous plaque exposure period). Histological studies in monkeys have shown that in acute defect models approximately 50–70% spontaneous regeneration can be expected, which may lead to difficulties in interpreting the results.³¹ Majzoub *et al.*¹⁷ achieved a bone regrowth of 3.63 mm in his case report. This result is comparable to the outstanding result

achieved by Heiji¹⁶ with the difference that the defect treated by Majzoub *et al.*¹⁷ was not created surgically but resulted from chronic periodontitis. Majzoub *et al.*¹⁷ reported that bone regrowth appeared to parallel new cementum deposition, which is in contrast to the other publications^{5,10,11} reporting new bone formation to be minimal compared to cementum deposition (results not shown).

Another interesting result reported by Majzoub *et al.*¹⁷ is the ankylosis of the experimental tooth in the furcation area. It can be speculated that the necrotizing effect of low-pH phosphoric acid might have impaired the vitality and subsequently the healing potential of precursor cells involved in cementum and connective tissue formation, which resulted in ankylosis.³²⁻³⁴ Root surface conditioning has been conventionally performed with 37% phosphoric acid with a pH value of one^{16,35,36} or with EDTA 24% at a neutral pH.³⁷⁻⁴¹ Although it has been shown that long-time etching at low pH jeopardizes periodontal healing,³² the low pH of phosphoric acid does not seem to impair bone regeneration when used according to the published protocols.^{16,17}

Regarding the distal infrabony defect, the flap supporting the circumferential structure leading to wound stability could be a possible explanation for the high amount of bone regrowth achieved by Majzoub *et al.*,¹⁷ since results from animal studies suggest that EMD results in less regeneration in non-supporting defects.^{18,20}

Due to its gel-like consistence, EMD has no space-providing properties in order to avoid collapsing of the flap into the defect in cases where anatomical structures do not support the flap. However, this space provision seems to be a prerequisite for bone regeneration.⁴²

The results of Polimeni *et al.*⁴² seem to be supported by the finding that EMD gives rise to more bone regrowth in smaller-sized one-wall defects compared to larger-sized one-wall defects.¹⁸ However, it should also be taken into account that the bone crest was narrower and, hence, more resorbed adjacent to the larger defects. As a result, the amount of regeneration was likely influenced by the position of the bone crest. In standardized nonsupporting one-wall defects, no difference between treatment with EMD and OFD could be determined. However, a statistically significant difference of OFD was achieved after adding a space-providing α -TCP cement to the EMD.²⁰ Sculean *et al.*⁶ and Sallum *et al.*²² also achieved more favorable results in terms of bone regrowth when EMD was combined with a space-providing GTR barrier membrane compared to EMD treatment alone. Differences in the study of Sculean *et al.*⁶ were not statistically significant, and combined treatment resulted in new bone formation comparable to GTR therapy alone. Membrane exposure and subsequent bacterial colonization and infection were frequently occurring complications in this study, which might explain why Sallum *et al.*²² found significantly better results for the combined treatment compared to EMD alone (only one exposed membrane). Surprisingly, Sallum *et al.*²² reported no difference between GTR alone and OFD. Interestingly, Onodera *et al.*¹⁹ determined that in the combined treatment procedure (GTR + EMD), EMD influenced new bone formation positively during the first 4 weeks of healing compared with GTR therapy alone, whereas no difference was apparent after week 8 of healing.

When treatment of infrabony defects with EMD alone is compared with OFD, most studies report significantly better

results for the EMD therapy.^{6,21,22} Unfortunately, supportive or nonsupportive structure (i.e., amount of bony walls) as well as the exact defect dimensions (width at the base of the pocket in orobuccal dimension, width in mesiodistal dimension, and height of the defect) are not reported in these articles, which makes it difficult to draw conclusions on the influence of anatomical factors.

Membrane exposure seemed to occur more frequently in monkey^{6,23} than in dog models.^{19,22,24,26} A possible explanation is that monkeys play with the sutures at the surgical site, which jeopardizes primary healing. It has been shown that membrane exposure with subsequent bacterial colonization and infection leads to a less-favorable treatment outcome.⁴³⁻⁴⁷

Regazzini *et al.*²⁵ reported significantly more new bone formation when EMD was applied in class II furcation defects, compared to OFD and the combined therapy (GTR + EMD). The authors of this study did not find a significant difference between the combined treatment and OFD. An explanation can be that membrane exposure is responsible for the treatment outcome of the combined group; unfortunately, the amount of sites that became exposed is not mentioned and could be minimal since the study was performed in dogs. The good treatment outcome for the EMD group could indicate that space-providing barrier membranes are not of major importance in class II furcation defects, since the tooth roots prevent collapse of the flap. Donos *et al.*²³ reported most favorable results for the combined therapy although differences to the EMD-alone group were negligible in the treatment of class III furcation defects. However, one out of three sites treated with the combined therapy (GTR + EMD) experienced membrane exposure that led to less-favorable results. The amount of new bone formation of the GTR-alone group was located between the other two test groups (GTR + EMD and EMD alone) and the OFD group, but it has to be taken into account that two out of three sites treated with GTR alone experienced membrane exposure. In the GTR-treated defect where membrane was not exposed, the defect had healed almost completely with bone. Whereas in those sites where the membrane became exposed, the amount of newly formed bone was minimal. On the other hand, only one of the three furcation defects treated with EMD alone had healed almost completely, which might suggest that treatment of class III furcation defects with EMD is unpredictable. In the assessment of bone fill in furcation class III defects in dogs, minimal formation was observed, limited to the basis of the defect in the three test groups studied (Table 3) without any statistical difference between the groups.²⁴ However, the number of animals is a weak point to be considered and a limitation to finding differences among groups.

Stenport and Johansson¹⁵ concluded in their study that EMD treatment does not contribute to bone formation around titanium implants in a rabbit model. The authors suggested that the model used was not ideal to study the effects of bone-stimulating proteins because of the large cortical area that had to be resorbed before osseointegration could occur. This theory is supported by the findings of Tonetti *et al.*,⁴¹ who reported in a clinical study that highly cortical and highly cancellous bone types negatively impacted the outcome of EMD treatment in infrabony defects. In contrast, the results of Shimizu *et al.*²⁷ suggest that EMD

increases the initial growth of trabecular bone around endosseous implants by new bone induction in the medullary cavities and maintains such bony support of implants by filling the surfaces with newly formed bone trabeculae. These newly formed bone trabeculae were immunoactive for bone sialoprotein (BSP), which is a noncollagenous bone matrix protein, and were localized at the mineralization site of developing bone.⁴⁸ BSP-positive trabecular bone formed after implantation is thought to be bone matrix produced by newly differentiated osteoblasts,⁴⁹ indicating that EMD promotes osteogenic differentiation of pluripotent mesenchymal cells. The results of Casati *et al.*²⁶ also indicate that EMD positively influences bone healing after GBR around titanium implants. EMD alone, however, had no statistically significant effect. The membrane could have provided a protected coagulum and also helped to avoid collapse of the flap into the dehiscence-type defect, supporting the results of Polimeni *et al.*⁴²

In contrast to the findings from Shimizu *et al.*,²⁷ BSP was only weakly observed in the newly formed trabecular bone of parietal bone defects; however, 60 days postoperation, new bone formation in EMD-applied defects was significantly greater than that seen in PGA-applied controls.³⁰ Using a Teflon capsule model, the study by Donos *et al.*²⁸ failed to support the hypothesis that the adjunctive application of EMD to GBR would positively influence the formation of new jaw bone outside the skeletal envelope. This finding is in accordance with the study by Murai *et al.*²⁹ who found no significant difference in promotion of new bone formation between β -TCP alone, and the combination of EMD and β -TCP within a titanium capsule, but in contrast to observations in which a positive influence on bone formation was seen following the application of EMD under a barrier membrane.^{22,26}

Conclusion

The findings of the studies should be considered with caution due to the small sample sizes. Small numbers of animals are frequently observed in the literature and are a consequence of the limitations when testing on larger animals, such as dogs and monkeys. In addition, direct extrapolation of data obtained from animal studies to humans should be interpreted cautiously. Further, small sample sizes and a lack of matching defects, due to obvious reasons, are the limitations in human histological trials.

Another very important point that needs to be mentioned is that the maximum time allowed for healing in the reviewed articles was 9 months, but bone regeneration seems to continue to increase over 36 months after EMD treatment.⁵⁰ Thus, bone regrowth might not be completed at the time of histological preparation.

The reviewed articles allow for the following conclusions:

Human studies have shown that GTR therapy of infrabony defects seems to result in a higher degree of bone regeneration than treatment with EMD. Animal studies suggest that EMD seems to lead to more bone regeneration of infrabony defects compared to OFD; however, EMD application might result in more bone formation when applied in supporting defects compared to nonsupporting defects. Further, most animal studies suggest that combined therapy

(GTR + EMD) of infrabony defects might not lead to better results than GTR therapy alone.

In animals, EMD seems to result in more bone formation compared to OFD in both furcation class II and III defects, but treatment of class III furcation defects with EMD is unpredictable. Additionally, there seems to be no additional benefit of combined therapy (GTR + EMD) in furcation defects.

EMD does not seem to promote external jaw/parietal bone formation in the titanium capsule model.

EMD might increase growth of trabecular bone around implants by new bone induction in the medullary cavities. However, when bony defects adjacent to dental implants have to be treated, combination with GBR procedures seems to lead to better results compared to application of EMD alone and GBR alone.

The cautious use of phosphoric acid for root conditioning prior to EMD application does not seem to influence bone regeneration negatively.

It might be suggested that EMD promotes osteogenic differentiation of pluripotent mesenchymal cells *in vivo*. Thus, EMD seems to promote bone formation, but the lack of space-providing properties might be a limiting factor. Further, an additional benefit of EMD in combination with a space-providing GTR technique seems to be limited.

For future studies, it would be desirable to mention the exact size of the infrabony defects because the width of the defect base seems to be especially crucial for determining the extent of bone regeneration.⁴² The amount of bony walls should also be mentioned in order to allow for further conclusions and easier comparison between studies.

Conflict of Interest and Source of Funding Statement

The authors declare that they have no conflict of interest. None of the authors received any benefit of any kind from commercial or official parties related directly or indirectly to the subject matter of this article. No grant or funding from any party was received to prepare or perform this work.

References

1. American Academy of Periodontology. Glossary of Periodontal Terms, fourth edition. Chicago, IL: AAP, 2001.
2. Trombelli, L., Heitz-Mayfield, L.J., Needleman, I., Moles, D., and Scabbia, A. A systematic review of graft materials and biologic agents for periodontal intraosseous defects. *J Clin Periodontol* **29**, 117, 2002.
3. Trombelli, L. Which reconstructive procedures are effective for treating the periodontal intraosseous defect? *Periodontol* **2000** **37**, 88, 2005.
4. Mellonig, J.T. Enamel matrix derivative for periodontal reconstructive surgery: technique and clinical and histologic case report. *Int J Periodontics Restorative Dent* **19**, 9, 1999.
5. Sculean, A., Donos, N., Windisch, P., Brex, M., Gera, I., Reich, E., and Karring, T. Healing of human intrabony defects following treatment with enamel matrix proteins or guided tissue regeneration. *J Periodont Res* **34**, 310, 1999.
6. Sculean, A., Donos, N., Windisch, P., Brex, M., Gera, I., Reich, E., and Karring, T. Treatment of intrabony defects with guided tissue regeneration and enamel matrix proteins: an experimental study in monkeys. *J Clin Periodontol* **27**, 4666, 2000.

7. Rasperini, G., Silvestri, M., Schenk, R.K., and Nevins, M.L. Clinical and histological evaluation of human gingival recession treated with a subepithelial connective tissue graft and enamel matrix derivative (Emdogain): a case report. *Int J Periodontics Restorative Dent* **20**, 269, 2000.
8. Yukna, A., and Mellonig, J. Histological evaluation of periodontal healing in humans following regenerative therapy with enamel matrix derivative. A 10-case series. *J Periodontol* **71**, 752, 2000.
9. Bosshardt, D.D., Sculean, A., Windisch, P., Pjetursson, B.E., and Lang, N.P. Effects of enamel matrix proteins on tissue formation along the roots of human teeth. *J Periodont Res* **40**, 158, 2005.
10. Sculean, A., Chiantella, G.C., Windisch, P., and Donos, N. Clinical and histologic evaluation of human intrabony defects treated with an enamel matrix protein derivative (Emdogain). *J Periodontics Restorative Dent* **20**, 375, 2000.
11. Windisch, P., Sculean, A., Klein, F., Toth, V., Gera, I., Reich, E., and Eickholz, P. Comparison of clinical, radiographic, and histometric measurements following treatment with guided tissue regeneration or enamel matrix proteins in human periodontal defects. *J Periodontol* **73**, 409, 2002.
12. Kawana, F., Sawae, Y., Sahara, T., Tanaka, S., Debari, K., Shimizu, M., and Sasaki, T. Porcine enamel matrix derivative enhances trabecular bone regeneration during wound healing of injured rat femur. *Anat Rec* **264**, 438, 2001.
13. Yoneda, S., Itoh, D., Kuroda, S., Kondo, H., Umezawa, A., Ohya, K., Ohyama, T., and Kasugai, S. The effects of enamel matrix derivative (EMD) on osteoblastic cells in culture and bone regeneration in a rat skull defect. *J Periodont Res* **38**, 333, 2003.
14. Suzuki, S., Nagano, T., Yamakoshi, Y., Gomi, K., Arai, M., Fukae, M., Katagiri, T., and Oida, S. Enamel matrix derivative gel stimulates signal transduction of BMP and TGF- β . *J Dent Res* **84**, 510, 2005.
15. Stenport, F., and Johansson, C.B. Enamel matrix derivative and titanium implants: an experimental pilot study in the rabbit. *J Clin Periodontol* **30**, 359, 2003.
16. Heijl, L. Periodontal regeneration with enamel matrix derivative in one human experimental defect: a case report. *J Clin Periodontol* **24**, 693, 1997.
17. Majzoub, Z., Bobbo, M., Atiyeh, F., and Cordioli, G. Two Patterns of histologic healing in an intrabony defect following treatment with enamel matrix derivative: a human case report. *Int J Periodontics Restorative Dent* **25**, 283, 2005.
18. Cochran, D.L., King, G.N., Schoofield, J., Velasquez-Plata, D., Mellonig, J.T., and Jones, A. The effect of enamel matrix proteins on periodontal regeneration as determined by histological analyses. *J Periodontol* **74**, 1043, 2003.
19. Onodera, H., Shibukawa, Y., Sugito, H., Ota, M., and Yamada, S. Periodontal regeneration in intrabony defects after application of enamel matrix proteins with guided tissue regeneration: an experimental study in dogs. *Biomed Res* **26**, 69, 2005.
20. Shirakata, Y., Yoshimoto, T., Goto, H., Yonamine, Y., Kadamatsu, H., Miyamoto, M., Nakamura, T., Hayashi, C., and Izumi, Y. Favourable periodontal healing of 1-wall intrabony defects after application of calcium phosphate cement wall alone or in combination with enamel matrix derivative: a pilot study with canine mandibles. *J Periodontol* **78**, 889, 2007.
21. Hammarström, L., Heijl, L., and Gestrelus, S. Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins. *J Clin Periodontol* **24**, 669, 1997.
22. Sallum, E.A., Pimentel, S.P., Saldanha, J.B., Nogueira-Filho, G.R., Casati, M.Z., Nociti, F.H., and Sallum, A.W. Enamel matrix derivative and guided tissue regeneration in the treatment of dehiscence type defects: a histomorphometric study in dogs. *J Periodontol* **75**, 1357, 2004.
23. Donos, N., Sculean, A., Glavind, L., Reich, E., and Karring, T. Wound healing of degree III furcation involvements following guided tissue regeneration and/or Emdogain®: a histologic study. *J Clin Periodontol* **30**, 1061, 2003.
24. Fernandes, J.M.A., Rego, R.O.C.C., Spolidorio, L.C., Marcantonio, R.A.C., Junior, E.M., and Cirelli, J.A. Enamel matrix proteins associated with GTR and bioactive glass in the treatment of class III furcation in dogs. *Braz Oral Res* **19**, 169, 2005.
25. Regazzini, P., Novaes, A.B., de Oliveira, P.T., Palioto, D.B., Taba, M., de Souza, S.L.S., and Grisi, M.F.M. Comparative study of enamel matrix derivative with or without GTR in the treatment of class II furcation lesions in dogs. *Int J Periodontics Restorative Dent* **24**, 476, 2004.
26. Casati, M.Z., Sallum, E.A., Nociti, F.H., Caffesse, R.G., and Sallum, A.W. Enamel matrix derivative and bone healing after guided bone regeneration in dehiscence-type defects around implants: a histomorphometric study in dogs. *J Periodontol* **73**, 789, 2002.
27. Shimizu-Ishiura, M., Tanaka, S., Lee, W.S., Debari, K., and Sasaki, T. Effects of enamel matrix derivative to titanium implantation in rat femurs. *J Biomed Mater Res* **60**, 269, 2002.
28. Donos, N., Bosshardt, D., Lang, N., Graziani, F., Tonetti, M., Karring, T., and Kostopoulos, L. Bone formation by enamel matrix proteins and xenografts: an experimental study in the rat ramus. *Clin Oral Implants Res* **16**, 140, 2005.
29. Murai, M., Shuichi, S., Koshi, R., Yokoyama, K., Ikeda, K., Narukawa, M., Takayama, T., Yoshinuma, N., and Ito, K. Effects of the enamel matrix derivative and β -tricalcium phosphate on bone augmentation within a titanium cap in rabbit calvarium. *J Oral Sci* **47**, 209, 2005.
30. Sawae, Y., Sahara, T., Kawana, F., and Sasaki, T. Effects of enamel matrix derivative on mineralized tissue formation during bone wound healing in rat parietal bone defects. *J Electron Microsc* **51**, 413, 2002.
31. Caton, J., Mota, L., Gandini, L., and Laskaris, B. Non-human primate models for testing the efficacy and safety of periodontal regeneration procedures. *J Periodontol* **64**, 1143, 1994.
32. Blomlöf, J., Hansson, L., Blomlöf, L., and Lindskog, S. Long-time etching at low pH jeopardizes periodontal healing. *J Clin Periodontol* **22**, 459, 1995.
33. Blomlöf, J., Hansson, L., Blomlöf, L., and Lindskog, S. Root surface etching at neutral pH promotes healing. *J Clin Periodontol* **23**, 50, 1996.
34. Blomlöf, J., and Lindskog, S. Periodontal tissue vitality after different etching modalities. *J Clin Periodontol* **22**, 464, 1995.
35. Parodi, R., Liuzzo, G., and Patrucco, P. Use of Emdogain in the treatment of deep intrabony defects: 12-month clinical results. Histologic and radiographic evaluation. *Int J Periodontics Restorative Dent* **20**, 585, 2000.
36. Sculean, A., Chiantella, G.C., Miliauskaitė, A., Brex, M., and Arweiler, N. Four-year results following treatment of intrabony periodontal defects with an enamel matrix protein derivative: a report of 46 cases. *Int J Periodontics Restorative Dent* **23**, 345, 2003.

37. Heden, G. A case report study of 72 consecutive Emdogain-treated intrabony periodontal defects: clinical and radiographic findings after 1 year. *Int J Periodontics Restorative Dent* **20**, 126, 2000.
38. Pontoriero, R., Wennström, J., and Lindhe, J. The use of barrier membranes and enamel matrix proteins in the treatment of angular bone defects. A prospective controlled clinical study. *J Clin Periodontol* **26**, 833, 1999.
39. Silverstri, M., Ricci, G., Rasperini, G., Sartori, S., and Cattaneo, V. Comparison of treatments of infrabony defects with enamel matrix derivative, guided tissue regeneration with a nonresorbable membrane and Widman modified flap. A pilot study. *J Clin Periodontol* **27**, 603, 2000.
40. Sculean, A., Windisch, P., Chiantella, G.C., Donos, N., Brex, M., and Reich, E. Treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration. A prospective controlled clinical study. *J Clin Periodontol* **28**, 397, 2001.
41. Tonetti, M.S., Lang, N.P., Cortellini, P., Suvan, J., Adrians, P., Dubravec, D., Fonzar, A., Fourmoussis, I., Mayfield, L., Rossi, R., Silverstri, M., Tiedemann, C., Topoll, H., Vangsted, T., and Wallkamm, B. Enamel matrix proteins in the regenerative therapy of deep intrabony defects. A multicentre randomized controlled clinical trial. *J Clin Periodontol* **29**, 317, 2002.
42. Polimeni, G., Albander, J.M., and Wikesjö, U.M.E. Prognostic factors for alveolar regeneration: effect of space provision. *J Clin Periodontol* **32**, 951, 2005.
43. Lindhe, J., Pontoriero, R., Berglundh, T., and Araujo, M. The effect of flap management and bioresorbable occlusive devices in GTR treatment of degree III furcation defects. An experimental study in dogs. *J Clin Periodontol* **22**, 236, 1995.
44. Ling, L.J., Hung, S.L., Lee, C.F., Chen, Y.T., and Wu, K.M. The influence of membrane exposure on the outcomes of guided tissue regeneration: clinical and microbiological aspects. *J Periodont Res* **38**, 57, 2003.
45. Nowzari, H., Matian, F., and Slots, J. Periodontal pathogens on polytetrafluoroethylene membrane for guided tissue regeneration inhibit healing. *J Clin Periodontol* **22**, 469, 1995.
46. Pontoriero, R., Nyman, S., Ericsson, I., and Lindhe, J. Guided tissue regeneration in surgically-produced furcation defects. An experimental study in the beagle dog. *J Clin Periodontol* **19**, 159, 1992.
47. Sander, L., and Karring, T. New attachment and bone formation in periodontal defects following treatment of submerged roots with guided tissue regeneration. *J Clin Periodontol* **22**, 295, 1995.
48. Chen, J.K., Zhang, Q., McCulloch, C.A., and Sodek, J. Immunohistochemical localization of bone sialoprotein in fetal porcine bone tissues: comparisons with secreted phosphoprotein 1 (SSP-1, osteopontin) and SPARC (osteonectin). *Histochem J* **23**, 281, 1991.
49. Bianco, P., Riminucci, M., Silvestrini, G., Bonucci, E., Termine, J.D., Fisher, L.W., and Robey, P.G. Localization of bone sialoprotein (BSP) to Golgi and post-Golgi secretory structures in osteoblasts and to discrete sites in early bone matrix. *J Histochem Cytochem* **41**, 193, 1993.
50. Heijl, L., Heden, G., Svärdröm, G., and Östgren, A. Enamel matrix derivative (Emdogain) in the treatment of intrabony periodontal defects. *J Clin Periodontol* **24**, 705, 1997.
51. Sculean, A., Windisch, P., Keglevich, T., and Gera, I. Clinical and histologic evaluation of an enamel matrix protein derivative combined with bioactive glass for the treatment of intrabony periodontal defects in humans. *Int J Periodontics Restorative Dent* **25**, 139, 2005.
52. Sculean, A., Donos, N., Brex, M., Karring, T., and Reich, E. Healing of fenestration-type defects following treatment with guided tissue regeneration or enamel matrix proteins: an experimental study in monkeys. *Clin Oral Invest* **4**, 50, 2000.
53. Nemcovsky, C.E., Zahavi, S., Moses, O., Kebudi, E., Artzi, Z., Beny, L., and Weinreb, M. Effect of enamel matrix derivative on healing of surgical supra-infrabony periodontal defects in the rat molar: a histomorphometric study. *J Periodontol* **77**, 996, 2006.
54. Koike, Y., Murakami, S., Matsuzaka, K., and Inoue, T. The effect of Emdogain® on ectopic bone formation in tubes of rat demineralised dentin matrix. *J Periodont Res* **40**, 385, 2005.
55. Kanazashi, M., Gomi, K., Nagano, T., Tanabe, T., Arai, T., and Fukae, M. The 17-kDa sheath protein in enamel proteins induces cementum regeneration in experimental cavities created in a buccal dehiscence model of dogs. *J Periodont Res* **41**, 193, 2006.
56. Gurinsky, B.S., Mills, M.P., and Mellonig J.T. Clinical evaluation of demineralized freeze-dried bone allograft and enamel matrix derivative versus enamel matrix derivative alone for the treatment of periodontal osseous defects in humans. *J Periodontol* **75**, 1309, 2004.
57. Donos, N., Kostopoulos, L., Tonetti, M., Karring, T., and Lang, K. The effect of enamel matrix proteins and deproteinized bovine bone mineral on heterotrophic bone formation. *Clin Oral Implants Res* **17**, 434, 2006.
58. Donos, N., Lang, K.P., Karoussis, I.K., Bosshardt, D., Tonetti, M., and Kostopoulos, L. Effect of GBR in combination with deproteinized bovine bone mineral and/or enamel matrix proteins on the healing of critical-size defects. *Clin Oral Implants Res* **15**, 101, 2004.
59. Boyan, B.D., Weesner, T.C., Lohmann, C.H., Andreacchio, D., Carnes, D.L., Dean, D.D., Cochran, D.L., and Schwartz, Z. Porcine fetal enamel matrix derivative enhances bone formation induced by demineralised freeze dried bone allograft *in vivo*. *J Periodontol* **71**, 1278, 2000.

Address correspondence to:

Florian Rathe, Dr. med. dent.

Department of Periodontology and Biomaterials

Radboud University Nijmegen Medical Centre

Philips van Leydenlaan 25

6525 EX Nijmegen

The Netherlands

E-mail: f.rathe@dent.umcn.nl

Received: January 30, 2008

Accepted: June 8, 2008

Online Publication Date: August 14, 2008